CureVac (NASDAQ:CVAC) Downgraded to "Neutral" Rating by UBS Group

CureVac (NASDAQ:CVAC - Get Free Report) was downgraded by investment analysts at UBS Group from a "strong-buy" rating to a "neutral" rating in a research note issued on Thursday, Marketbeat.com reports. They presently have a $5.50 target price on the stock, down from their prior target price of $12.00. UBS Group's price objective suggests a potential upside of 1.29% from the stock's current price.

Other analysts have also recently issued research reports about the stock. JMP Securities reaffirmed a "market outperform" rating and set a $10.00 price objective on shares of CureVac in a research note on Wednesday, May 28th. Citizens Jmp cut shares of CureVac from a "strong-buy" rating to a "hold" rating in a research note on Thursday, June 12th. Citigroup cut shares of CureVac to a "market perform" rating in a research note on Thursday, June 12th. Finally, Jefferies Financial Group reaffirmed a "hold" rating and set a $5.00 price objective (down previously from $7.00) on shares of CureVac in a research note on Friday, June 13th. Four investment analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $6.83.

CureVac Stock Up 0.9%

Shares of NASDAQ CVAC opened at $5.43 on Thursday. CureVac has a 12-month low of $2.37 and a 12-month high of $5.72. The stock has a market cap of $1.22 billion, a PE ratio of 5.90 and a beta of 2.49. The company has a current ratio of 7.65, a quick ratio of 7.64 and a debt-to-equity ratio of 0.05. The company has a 50-day moving average of $4.28 and a 200 day moving average of $3.67.

CureVac (NASDAQ:CVAC - Get Free Report) last announced its quarterly earnings data on Thursday, May 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a net margin of 35.44% and a return on equity of 30.89%. The business had revenue of $0.94 million for the quarter, compared to analysts' expectations of $4.27 million. As a group, sell-side analysts predict that CureVac will post 0.72 EPS for the current fiscal year.

Institutional Trading of CureVac

Hedge funds have recently made changes to their positions in the company. Greenleaf Trust purchased a new stake in shares of CureVac in the 1st quarter valued at approximately $31,000. Integrated Wealth Concepts LLC grew its stake in shares of CureVac by 25.0% in the 1st quarter. Integrated Wealth Concepts LLC now owns 15,000 shares of the company's stock valued at $42,000 after buying an additional 3,000 shares during the period. Two Sigma Advisers LP purchased a new stake in shares of CureVac in the 4th quarter valued at approximately $48,000. Jump Financial LLC purchased a new stake in shares of CureVac in the 4th quarter valued at approximately $55,000. Finally, D. E. Shaw & Co. Inc. purchased a new stake in shares of CureVac in the 4th quarter valued at approximately $66,000. Hedge funds and other institutional investors own 17.26% of the company's stock.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.